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Abstract 
Purpose: To determine the effect of dietary soy isoflavone supplementation on bone loss in 
ovariectomized (OVX) rats. 
Methods: Forty-eight rats were assigned randomly to groups of OVX rats receiving soy isoflavones (20, 
30, or 40 mg/kg of body weight daily), untreated OVX rats, or untreated intact rats. After 8 weeks, bone 
mineral density (BMD), mineral (Ca, P, Mn, Mg, and Zn) concentrations, and the expression of 
osteoblast-related genes were measured in femur tissue samples. 
Results: Eight weeks after OVX, there was a significant decrease in body weight, serum levels of 
osteocalcin, alkaline phosphatase, and oestradiol, BMD and mineral elements, as well as the 
expressions of Ctnnb1, Runx2, and Sp7 (all p < 0.05). These decreases were accompanied by reduced 
maximum load capacity of lumbar vertebrae. Daily supplementation with soy isoflavones dose-
dependently ameliorated these effects (all p < 0.05). Western blotting revealed that these effects were 
likely due to the reversal of the OVX-induced decrease in Notch1 proteins in bone and muscle. 
Conclusion: Soy isoflavone treatment represents a potential therapy for preventing postmenopausal 
bone loss by stimulating the Notch signalling. 
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Postmenopausal osteoporosis is a common 
condition in which reduced levels of oestrogen 
alter the mineral composition of bone, leading to 
a loss of mineralized bone tissue and structural 
failure (fracture) [1–4]. To delay the loss of bone 
minerals and thereby prevent bone fractures, 
treatment strategies have included oestrogen 
replacement or the administration of selective 
oestrogen receptor modulators, such as 
raloxifene, bisphosphonates, and calcitonin. 
However, these therapies increase the risk of 
hypercalcemia, hypercalciuria, hot flushes, and 
endometrial cancer [5-7]. 
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Interestingly, isoflavones are chemically similar 
to oestradiol (E2) and bind to both alpha- and 
beta-oestrogen receptors, resulting in either the 
stimulation of globulin production or inhibition of 
aromatase activity [8]. There is evidence that 
isoflavones reduce the risk of endometrial cancer 
by interfering with oestrogen hormone production 
and signalling. As a subclass of plant-based 
polyphenols, isoflavones are present in legumes 
and are in particularly high concentrations in soy 
products [8]. Thus, the dietary intake of these 
compounds may influence the deposition of 
minerals in bone tissue in individuals with low 
levels of oestrogen.  
 
In this study, we examined whether the intake of 
dietary soy isoflavones impacts bone mineral 
density (BMD) to prevent bone loss in animals 
with oestrogen deficiencies. For this, we 
analysed the mineral composition and 
transcription of osteoblast-related genes in 
vertebral and femur tissues from ovariectomized 
(OVX) rats, which have been shown to 





Isolation and HPLC analysis of soy 
isoflavones 
 
Soy isoflavones were isolated from defatted soy 
flour. Briefly, the flour was mixed with 100 mL of 
a methanol-water solution (4:1 ratio) in a 150-mL 
glass tube that was rotated for 3 h at 30 rpm at 
35 ± 0.1C. The solution was then placed under 
vacuum in a rotary evaporator to concentrate the 
extracts, which were then filtered and stored at -
80°C. 
 
The extracts were analysed by high-performance 
liquid chromatography (HPLC) using an HPLC 
system (Waters 2459; Waters Corp., Milford, MA, 
USA) with a 5-µm (4.6 × 250 mm) Waters Sunfire 
C18 column maintained at 25C. HPLC was 
conducted with 20-μL injections, a 0.9-ml/min 
flow rate (Waters 515 HPLC pump), a 210-nm 
detection wavelength, and a run time of 30 min. 
For the mobile phase, we used an isopropanol 
and acetonitrile mixture (1:24 [vol/vol]). Solutions 
of glycitin, daidzin, genistin daidzein, genistein, 




Forty-eight female wistar rats (3 months old; 230-
250 g) were assigned randomly to groups of 
OVX rats receiving daily soy isoflavones (20, 30, 
or 40 mg/kg of body weight), untreated OVX rats, 
or untreated intact rats. Rats were anaesthetized 
with pentobarbital for surgeries to remove both 
ovaries; in the intact rats, the ovaries were 
exposed but not removed. The animals receiving 
treatments were given oral (intragastric 
administration) doses of isoflavones once daily 
for 8 weeks. The procedures in this study were 
approved by the ethics committee of Dalian 
Medical University.  
 
All experimental protocols were approved by the 
Ethics Committee of Dalian Medical University 
(approval no. 170616) according to the 
guidelines put forth by the National Institutes of 
Health Guide for the Care and Use of Laboratory 
Animals [10]. 
 
Assessment of BMD and composition 
 
After 8 weeks, animals were anesthetized with 
pentobarbital for the measurement of the BMD of 
the lumbar vertebrae (L2 to L4) and the left 
femurs by dual-energy X-ray absorptiometry 
(Lunar, USA) as described previously [11]. The 
animals were sacrificed by CO2 asphyxiation, 
and the length and width of each femur 
(midshaft) were measured with digital callipers. 
The concentrations of Ca, P, Mn, Mg, and Zn in 
bone tissue were determined by atomic 
absorption spectrometry (Type 180–70; Hitachi 




Blood samples were collected prior to 
asphyxiation, and the resulting serum obtained 
after centrifugation (20 min at 3,000 rpm) was 
stored at -2 oC. Alkaline phosphatase (ALP) 
activities in serum were assayed with standard 
commercial colorimetric kits (ZhongSheng 
BeiKong Bio-technology and Science, China) on 
an automatic biochemical analyser (Cobas 
Integra 400 Plus; Roche Diagnostics, 
Switzerland). A double-antibody 
radioimmunoassay kit was used to determine 
osteocalcin (BGP) and E2 levels on a gamma-
ray counter [12]. 
 
Quantitative real-time PCR 
 
Trizol reagent (Invitrogen) was used to extract 
total RNA from bone tissues for quantitative real-
time PCR with SYBR green on a Light Cycler 
480 II (Roche Diagnostics). The expressions of 
osteoblast-specific osterix (Sp7), -catenin 
(Ctnnb1), runt-related transcription factor 2 
(Runx2), and -actin (Actb; reference gene) were 
determined by using the primers listed in Table 1. 
Each reaction was performed in triplicate and 
was repeated three times. Relative cycle 
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threshold (CT) values were used to quantify gene 
expression according to the 2-CT method. 
 
























Total proteins from 50-mg samples of bone and 
muscle tissue were extracted with RIPA lysis 
buffer. A BCA protein assay (Pulilai, China) was 
used to measure protein concentrations. Protein 
samples (80 μg) were separated by SDS-PAGE 
on 10 % gels and transferred to polyvinylidene 
difluoride membranes. The membranes were first 
incubated for 3 h in 5% non-fat-milk blocking 
solution at room temperature, followed by an 
overnight incubation at 4C with anti-Notch1 or 
anti-Gapdh antibodies (1:1,000). After incubating 
with appropriate secondary antibodies, the 
proteins were visualized via enhanced 
chemiluminescence. The densities of the bands 
for each protein were measured using ImageJ 
(National Institutes of Health, USA), and Notch1 




Data are presented as mean ± SD and were 
analysed by one-way analysis of variance using 
SPSS software (version 12.0). P <0.05 was 




The isoflavone composition of the extracts was 
2.13479 ng/μL genistin, 13.86087 ng/μL glycitin, 
4.15441 ng/μL daidzin, 32.23469 ng/μL 
genistein, and 34.26970 ng/μL daidzein, (Figure 
1). 
 
Ovariectomy significantly reduced the mean 
BMD values after 8 weeks (p < 0.05) (Figure 3). 
However, daily soy isoflavone supplementation 




Figure 1: HPLC chromatogram of soy isoflavones 
 
The average initial and final body weights from 
all groups are presented in Figure 2. Over the 8-
week study, the body weights of all animals 
increased; however, the OVX rats were 
significantly heavier than those of the intact 
group (p < 0.05). Isoflavone supplementation 
attenuated the weight increase over the 8-week 
study in a dose-dependent manner. 
 
 
Figure 2: Soy isoflavone supplementation suppresses 
weight gain in OVX rats. 1, intact rats; 2, untreated 
OVX rats; 3–5, OVX rats treated with 20, 30, or 40 
mg/kg isoflavones, respectively; *p < 0.05, **p < 0.01 
 



















Figure 3: Soy isoflavone supplementation suppresses 
the reduction of BMD (g/cm2) in OVX rats. 1, intact 
rats; 2, untreated OVX rats; 3–5, OVX rats treated with 
20, 30, or 40 mg/kg isoflavones, respectively; *p < 
0.05, **p < 0.01 
 
Serum levels of BGP, ALP, and E2 measured 
after 8 weeks were significantly (p < 0.01) higher 
in intact rats than in OVX rats (Table 2). 
Furthermore, the administration of soy 
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isoflavones dose-dependently increased serum 
BGP, ALP, and E2 levels in OVX rats.  
 
Table 2: Serum BGP, ALP and E2 levels 
 


















OVX + 20 
mg/kg 























Daily soy isoflavone supplementation also 
affected the concentrations of Ca, P, Mg, Mn, 
and Zn in bone tissues as shown in Table 3. The 
levels of all elements were significantly higher in 
intact rats than in untreated OVX rats. However, 
the administration of soy isoflavones to OVX rats 
significantly and dose-dependently increased Ca, 
P, Mg, Mn, and Zn concentrations compared to 
those in the untreated OVX model group. 
 

































Figure 4: Soy isoflavone supplementation increases 
the maximum load capacity of lumbar vertebrae. 1, 
intact rats; 2, untreated OVX rats; 3–5, OVX rats 
treated with 20, 30, or 40 mg/kg isoflavones, 
respectively; **p < 0.05 
 
The maximum lumbar load capacity was 
significantly reduced after 8 weeks in OVX rats 
(Figure 4). However, animals receiving 
isoflavone supplementation demonstrated 
significantly higher (p < 0.05) load capacities 
than those of the untreated OVX rats, an effect 
that also appeared to be dose dependent. 
 
We also measured gene expression levels in 
bone tissue samples. We found that relative to 
the levels in intact animals, the transcription of 
genes encoding β-catenin, runt-related 
transcription factor 2, and osterix (Ctnnb1, 
Runx2, and Sp7, respectively) were reduced in 
the femurs of OVX rats (Table 4). However, the 
levels of all three transcripts were significantly 
higher (p < 0.05) in the OVX rats that were 
treated with soy isoflavones, with the largest 
difference observed with the high-dose soy 
isoflavone treatment. 
  
Table 4: Gene expression in femur tissue 
 
Group  Ctnnb1 Runx2 Sp7 










OVX + 20 
mg/kg 




OVX + 30 
mg/kg 




OVX + 40 
mg/kg 





We also examined the protein expression of 
Notch1 in samples of femur and muscle tissue. 
There was a dramatic loss of Notch1 protein in 
the femurs and muscles of OVX rats (Figure 5 A 
and B, respectively). However, daily treatment 
with soy isoflavones increased the expression of 
Notch1 protein significantly (p < 0.05) in OVX 
rats. The effect was most pronounced in animals 




The loss of bone and bone strength in individuals 
with osteoporosis contributes to fractures as a 
result of longer durations of resorption phases 
during bone remodelling [13]. During 
menopause,  this  enhancement of  bone resorpt- 
Table 3: Concentration of minerals in bone 
 
Group Ca (μg/g) P (μg/g) Mg (μg/g) Mn (μg/g) Zn (μg/g) 






0.93 ± 0.03 392.15 ± 
16.21 






0.81 ± 0.04 362.71 ± 
18.48 






0.85 ± 0.05 371.06 ± 
20.51 






0.88 ± 0.03 379.14 ± 
22.15 






0.91 ± 0.04 387.46 ± 
19.59 
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Figure 5: Soy isoflavone supplementation restores 
Notch1 protein expression in femur (A) and muscle (B) 
tissue. 1, intact rats; 2, untreated OVX rats; 3–5, OVX 
rats treated with 20, 30, or 40 mg/kg isoflavones, 
respectively; *p < 0.05, **p < 0.01   
 
tion is at the expense of osteoplastic 
replacement, resulting in reduced bone formation 
[14,15]. 
 
Thus, we examined whether isoflavones, which 
can mimic some of the actions of oestrogen, can 
influence this process and suppress bone loss. It 
was observed that supplementation with dietary 
soy isoflavones inhibited OVX-induced 
osteoporosis in rats. The effect was observed in 
BMD and serum levels of ALP and BGP, which 
are indicators of bone formation and turnover. 
Whereas ALP catalyses osteoid formation and 
bone mineralization, BGP is a non-collagenous 
protein that regulates bone mineralization and 
suppresses abnormal hydroxyapatite 
crystallization and cartilage mineralization, 
thereby balancing bone remodelling processes 
[16-18]. Accordingly, we observed that OVX 
animals treated with soy isoflavones had 
increased concentrations of Ca, P, Mg, Mn, and 
Zn in bone, which are indicators of the mineral 
content and degree of mineralization in bone 
tissue [19]. Moreover, soy isoflavones dose-
dependently restored the transcription of 
osteoblast-related genes (Ctnnb1, Runx2, and 
Sp7) in OVX rats. Thus, the high-dose 
administration of soy isoflavones inhibited the 
OVX-induced bone loss, which was 
demonstrated by an increase in the maximum 
load capacity of lumbar vertebrae. 
 
Notch1 is one of the four Notch proteins, which 
are transmembrane receptors that regulate 
highly conserved cell-fate decisions during 
embryonic development and throughout 
adulthood, including in the placenta during 
pregnancy [20]. Notch1 also regulates the 
differentiation and decidualization of stromal cells 
in the endometrium [20]. The expression of 
Notch1 dropped dramatically in OVX rats but was 





The results demonstrate that soy isoflavones 
inhibit bone loss and alleviate osteoporosis in 
rats, in part, via upregulation of Notch signalling. 
This suggests that soy isoflavones can 
potentially be applied to mitigate the effects of 
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